I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy

Background Brain atrophy, as assessed by magnetic resonance imaging (MRI), has been correlated with disability in patients with multiple sclerosis (MS). Recent evidence indicates that both white matter (WM) and gray matter (GM) are subject to atrophy in patients with MS. Although neurological deficiencies in MS are primarily due to loss of WM, the clinical significance of GM atrophy has not been fully explored in MS. Methods We have undertaken a three-year, open-label study, comparing 26 patients who elected to receive intramuscular interferon beta-1a (IFN β-1a) therapy, with 28 patients who elected not to receive therapy. Both groups had quantitative cranial MRI scans at study entry and after three years, and standardized clinical assessments every six months. Brain parenchymal fraction (BPF), GM fraction (GMF), and WM fraction (WMF) percent changes were calculated, and T2- and T1-lesion volumes (LVs) assessed. Results After three years, mean percent (%) change in BPF favored the IFN β-1a treatment group (IFN β-1a —1.3% versus the control group —2.5%, P=0.009), as did the mean percent change in GMF (+0.2 versus —1.4%, P=0.014), and the mean percent change in T1-LV (—9.3 versus +91.6%, P=0.011). At the end of the study, there was a significant within-patient decrease in BPF for both groups (P=0.02 for the IFN β-1a treatment group, and P<0.001 for the control group), a significant within-patient decrease in WMF for the IFN β-1a treatment group (P=0.01), and a significant decrease in GMF for the control group (P=0.013) when compared with baseline. Conclusion Over a three-year period, treatment with IFN β-1a significantly slowed the progression of whole-brain and GM atrophy, and of T1-hypointense LV accumulation, when compared with the control group. Multiple Sclerosis 2007; 13: 490-501. http://msj.sagepub.com

[1]  Rohit Bakshi,et al.  Central Nervous System Atrophy and Clinical Status in Multiple Sclerosis , 2004, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[2]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[3]  Rohit Bakshi,et al.  Correction for intracranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method , 2004, NeuroImage.

[4]  Rohit Bakshi,et al.  Regional lobar atrophy predicts memory impairment in multiple sclerosis. , 2005, AJNR. American journal of neuroradiology.

[5]  D. Louis Collins,et al.  Relating neocortical pathology to disability progression in multiple sclerosis using MRI , 2004, NeuroImage.

[6]  Alan J Thompson,et al.  The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM‐based segmentation methodology , 2002, Journal of magnetic resonance imaging : JMRI.

[7]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[8]  Rohit Bakshi,et al.  Thalamic Involvement in Multiple Sclerosis: A Diffusion‐Weighted Magnetic Resonance Imaging Study , 2003, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[9]  F. Barkhof,et al.  Cortical lesions in multiple sclerosis. , 1999, Brain : a journal of neurology.

[10]  B. Trapp,et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.

[11]  J K Udupa,et al.  Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. , 2000, Radiology.

[12]  G. Linazasoro,et al.  Conversion from dopamine agonists to pramipexole , 2004, Journal of Neurology.

[13]  Hans Lassmann,et al.  Cortical demyelination and diffuse white matter injury in multiple sclerosis. , 2005, Brain : a journal of neurology.

[14]  David H. Miller,et al.  Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. , 2002, Brain : a journal of neurology.

[15]  M. F. Fuller,et al.  Practical Nonparametric Statistics; Nonparametric Statistical Inference , 1973 .

[16]  G J Barker,et al.  The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. , 2000, Brain : a journal of neurology.

[17]  Rohit Bakshi,et al.  The relationship between whole brain volume and disability in multiple sclerosis: A comparison of normalized gray vs. white matter with misclassification correction , 2005, NeuroImage.

[18]  Bernice W. Polemis.  Nonparametric Statistics for the Behavioral Sciences , 1959 .

[19]  M Rovaris,et al.  Evidence for progressive gray matter loss in patients with relapsing-remitting MS , 2005, Neurology.

[20]  L. Kappos,et al.  A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS , 2002, Neurology.

[21]  A. Thompson,et al.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[22]  Karl J. Friston,et al.  Voxel-Based Morphometry—The Methods , 2000, NeuroImage.

[23]  Alireza Minagar,et al.  Gray Matter Involvement in Multiple Sclerosis: A New Window into Pathogenesis , 2003, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[24]  L. Kappos,et al.  Neutralizing antibodies and efficacy of interferon β-1a , 2005, Neurology.

[25]  P. M. Matthews,et al.  Evidence of early cortical atrophy in MS , 2003, Neurology.

[26]  A. Bertolotto,et al.  Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis , 2004, Neurology.

[27]  Alan J. Thompson,et al.  Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis , 2004, NeuroImage.

[28]  A J Thompson,et al.  Gray and white matter volume changes in early RRMS , 2005, Neurology.

[29]  Robert Zivadinov,et al.  Reproducibility and Accuracy of Quantitative Magnetic Resonance Imaging Techniques of Whole‐Brain Atrophy Measurement in Multiple Sclerosis , 2005, Journal of Neuroimaging.

[30]  Robert Zivadinov,et al.  Frontal parenchymal atrophy measures in multiple sclerosis , 2004, Multiple sclerosis.

[31]  Bruno Alfano,et al.  Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load , 2003, NeuroImage.

[32]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[33]  B. Lewis,et al.  Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFN&bgr;-1b , 2002, Neurology.

[34]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[35]  P. Carrieri,et al.  Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory , 2002, Journal of neurology, neurosurgery, and psychiatry.

[36]  R. Rudick,et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.

[37]  Rohit Bakshi,et al.  The measurement and clinical relevance of brain atrophy in multiple sclerosis , 2006, The Lancet Neurology.

[38]  Elizabeth Fisher,et al.  Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications , 2005, Multiple sclerosis.

[39]  Marco Rovaris,et al.  Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[40]  C. W. Tjoa,et al.  MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis , 2005, Journal of the Neurological Sciences.

[41]  N. De Stefano,et al.  Neocortical volume decrease in relapsing–remitting MS patients with mild cognitive impairment , 2004, Neurology.

[42]  G. Barker,et al.  Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques. , 1996, Magnetic resonance imaging.

[43]  David H. Miller,et al.  Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. , 2004, Brain : a journal of neurology.

[44]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[45]  R. Zivadinov,et al.  Role of Magnetic Resonance Imaging in the Diagnosis and Prognosis of Multiple Sclerosis , 2005 .

[46]  Lublin Fd,et al.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. , 1996 .

[47]  J. Simon.  Brain and spinal cord atrophy in multiple sclerosis. , 2000, Neuroimaging clinics of North America.

[48]  A J Thompson,et al.  Brain atrophy in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.

[49]  J H Simon,et al.  Eight-year follow-up study of brain atrophy in patients with MS , 2002, Neurology.

[50]  Rohit Bakshi,et al.  Short-term brain atrophy changes in relapsing–remitting multiple sclerosis , 2004, Journal of the Neurological Sciences.

[51]  A. Dale,et al.  Focal thinning of the cerebral cortex in multiple sclerosis. , 2003, Brain : a journal of neurology.

[52]  Mara Cercignani,et al.  Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. , 2005, Brain : a journal of neurology.

[53]  A J Thompson,et al.  Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. , 1996, Brain : a journal of neurology.

[54]  Robert Zivadinov,et al.  Semi-automatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MS , 2006, NeuroImage.

[55]  C H Polman,et al.  Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone , 2002, Multiple sclerosis.

[56]  R. Rudick,et al.  Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS , 2001, Neurology.

[57]  Rohit Bakshi,et al.  Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study , 2003, Neuroreport.

[58]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[59]  E. Radue,et al.  Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a , 2005, Neurology.

[60]  Rohit Bakshi,et al.  Role of MRI in multiple sclerosis I: inflammation and lesions. , 2004, Frontiers in bioscience : a journal and virtual library.

[61]  Rohit Bakshi,et al.  Role of MRI in multiple sclerosis II: brain and spinal cord atrophy. , 2004, Frontiers in bioscience : a journal and virtual library.

[62]  Marco Rovaris,et al.  Interferon beta-1 a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis : a randomised , double-blind , placebo-controlled trial , 2004 .